DrugCite
Search

EBIXA

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Ebixa Adverse Events Reported to the FDA Over Time

How are Ebixa adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Ebixa, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Ebixa is flagged as the suspect drug causing the adverse event.

Most Common Ebixa Adverse Events Reported to the FDA

What are the most common Ebixa adverse events reported to the FDA?

Malaise
18 (1.62%)
Oedema Peripheral
16 (1.44%)
Condition Aggravated
15 (1.35%)
Fall
15 (1.35%)
Confusional State
14 (1.26%)
Convulsion
14 (1.26%)
General Physical Health Deteriorati...
14 (1.26%)
Loss Of Consciousness
14 (1.26%)
Abnormal Behaviour
13 (1.17%)
Dyspnoea
13 (1.17%)
Dehydration
11 (.99%)
Show More Show More
Vomiting
11 (.99%)
Asthenia
10 (.9%)
Bradycardia
10 (.9%)
C-reactive Protein Increased
10 (.9%)
Disorientation
10 (.9%)
Lung Infection
10 (.9%)
Renal Failure
10 (.9%)
Renal Failure Acute
10 (.9%)
Alanine Aminotransferase Increased
9 (.81%)
Aspartate Aminotransferase Increase...
9 (.81%)
Blood Pressure Increased
9 (.81%)
Gait Disturbance
9 (.81%)
Septic Shock
9 (.81%)
Syncope
9 (.81%)
Conjunctivitis
8 (.72%)
Cough
8 (.72%)
Hallucination
8 (.72%)
Hypertension
8 (.72%)
Pulmonary Embolism
8 (.72%)
Rales
8 (.72%)
Rash Maculo-papular
8 (.72%)
Thrombocytopenia
8 (.72%)
Tremor
8 (.72%)
Febrile Neutropenia
7 (.63%)
Gamma-glutamyltransferase Increased
7 (.63%)
Lung Disorder
7 (.63%)
Pyrexia
7 (.63%)
Transient Ischaemic Attack
7 (.63%)
Anaemia
6 (.54%)
Anorexia
6 (.54%)
Creatinine Renal Clearance Decrease...
6 (.54%)
Eosinophil Count Increased
6 (.54%)
Grand Mal Convulsion
6 (.54%)
Haemoglobin Decreased
6 (.54%)
Hyperkalaemia
6 (.54%)
Hypertonia
6 (.54%)
Pancreatitis
6 (.54%)
Rash Erythematous
6 (.54%)
Somnolence
6 (.54%)
Weight Decreased
6 (.54%)
Acute Pulmonary Oedema
5 (.45%)
Aggression
5 (.45%)
Agitation
5 (.45%)
Anxiety
5 (.45%)
Blood Creatine Phosphokinase Increa...
5 (.45%)
Blood Thyroid Stimulating Hormone I...
5 (.45%)
Blood Urea Increased
5 (.45%)
Bronchospasm
5 (.45%)
Disturbance In Attention
5 (.45%)
Drug Interaction
5 (.45%)
Epilepsy
5 (.45%)
Extrapyramidal Disorder
5 (.45%)
Leukopenia
5 (.45%)
Musculoskeletal Stiffness
5 (.45%)
White Blood Cell Count Decreased
5 (.45%)
Atrial Fibrillation
4 (.36%)
Blood Creatinine Increased
4 (.36%)
Blood Phosphorus Increased
4 (.36%)
Bundle Branch Block Left
4 (.36%)
Bundle Branch Block Right
4 (.36%)
Coma
4 (.36%)
Crepitations
4 (.36%)
Delirium
4 (.36%)
Dizziness
4 (.36%)
Drug Ineffective
4 (.36%)
Dyspnoea Exertional
4 (.36%)
Flushing
4 (.36%)
Gastroenteritis
4 (.36%)
Hypotension
4 (.36%)
Metabolic Acidosis
4 (.36%)
Ophthalmoplegia
4 (.36%)
Parkinsonism
4 (.36%)
Physical Assault
4 (.36%)
Pulmonary Oedema
4 (.36%)
Rash Macular
4 (.36%)
Sepsis
4 (.36%)
Strabismus
4 (.36%)
Transaminases Increased
4 (.36%)
Urinary Tract Infection
4 (.36%)
Apathy
3 (.27%)
Aphasia
3 (.27%)
Bedridden
3 (.27%)
Cerebrovascular Accident
3 (.27%)
Cognitive Disorder
3 (.27%)
Dementia
3 (.27%)
Depressed Level Of Consciousness
3 (.27%)
Diabetic Hyperosmolar Coma
3 (.27%)
Dyskinesia
3 (.27%)
Electroencephalogram Abnormal
3 (.27%)
Eosinophilia
3 (.27%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Ebixa, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Ebixa is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Ebixa

What are the most common Ebixa adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Ebixa, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Ebixa is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Ebixa According to Those Reporting Adverse Events

Why are people taking Ebixa, according to those reporting adverse events to the FDA?

Dementia Alzheimers Type
142
Dementia
28
Drug Use For Unknown Indication
16
Abnormal Behaviour
5
Memory Impairment
4
Senile Dementia
4
Show More Show More
Cognitive Disorder
3
Vascular Dementia
2
Parkinsons Disease
2
Depression
2
Prophylaxis
2
Product Used For Unknown Indication
1
Cerebral Disorder
1
Glaucoma
1
Psychotic Disorder
1
Parkinsonism
1

Ebixa Case Reports

What Ebixa safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Ebixa. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Ebixa.